Physician profile
Bente H Berman
NPI 1205913910
$2,327.64
in general payments reported to CMS, 2019-2025
32 companies · $94.27 in 2025
The $94.27 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $387 · 2021: $341 · 2022: $217 · 2023: $142 · 2024: $83.97 · 2025: $94.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $320.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $422.22 | 2019 | |
| Sun Pharmaceutical Industries INC. | $242.82 | 2019-2025 | |
| Galderma Laboratories, L.P. | $238.85 | 2019-2025 | Aklief |
| Allergan, INC. | $167.73 | 2019-2022 | |
| Leo Pharma INC. | $163.05 | 2019-2025 | Anzupgo |
| Janssen Biotech, INC. | $142.98 | 2020-2023 | Tremfya |
| Novartis Pharmaceuticals Corporation | $106.52 | 2020-2023 | |
| Celgene Corporation | $105.22 | 2019 | |
| Pfizer INC. | $76.12 | 2019-2023 | |
| Lilly USA, LLC | $69.36 | 2019-2020 | |
| Ucb, INC. | $50.00 | 2019 | |
| Glenmark Therapeutics INC. | $46.00 | 2019 | |
| Genzyme Corporation | $38.29 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.87 | 2020 | |
| Abbvie INC. | $35.57 | 2022-2023 | Skyrizi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $29.32 | 2024 | Opzelura |
| Medtronic Vascular, INC. | $28.96 | 2020 | |
| Organogenesis INC. | $28.21 | 2024 | |
| Epi Health, LLC | $27.68 | 2019-2020 | |
| Botanix Sb INC | $27.57 | 2025 | Sofdra |
| Prugen, INC. Pharmaceuticals | $27.25 | 2019-2020 | |
| Dermavant Sciences, INC. | $26.44 | 2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $24.11 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $22.00 | 2019 | |
| Journey Medical Corporation | $21.90 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $21.06 | 2020 | |
| Mission Pharmacal Company | $20.06 | 2019 | |
| Dusa Pharmaceuticals, INC. | $20.00 | 2019 | |
| Encore Dermatology INC. | $18.85 | 2020 | |
| Verrica Pharmaceuticals INC. | $15.23 | 2023 | Ycanth |
| Mayne Pharma Commercial LLC | $14.52 | 2019 | |
| Sebela Pharmaceuticals INC. | $13.88 | 2023 | Naftin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bente Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.